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Abstract
The present research aimed at studying the atrial and brain natriuretic peptide (NUP) levels in the blood plasma of patients with 
Metabolic Syndrome (MS). The research includes 52 patients in total, of which 40 patients with MS constitute the observation group 
while 12 conventionally healthy people comprise the control group. An increase in the NT-proBNP at 20% (p<0.05) and proANP at 
67.8% (p<0.05) was observed in the blood plasma of the patients with MS. We observed a strong correlation between the atrium and 
brain NUP in the plasma and insulin and the insulin resistance index (IRI) that allows us to consider the NUP levels as the markers of 
early diagnosis of MS. 
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Introduction
The potential use of the circulating NUP levels as 
biochemical markers of myocardial dysfunction severity and 
predictors of prognosis in patients with cardiovascular disease 
is now being widely discussed. Along with the traditional risk 
factors, new biomarkers of cardiovascular complications - NUP 
- have independent prognostic value for cardiovascular disease. 
At present, the NUP system is known to consist of ANP, BNP, 
C-natriuretic peptide and its renal form – urodilatin [1, 4, 3, 5]. 
Atrial and brain NUP are secreted by the myocardial cells in 
response to pressure by load and volume,  and their biological 
effects include diuresis, natriuresis, vasodilation, suppression 
of the RAAS and  endothelial systems. NUP is continuously 
released from the cardiomyocytes, although the relevant 
mechanical and / or neuroendocrine stimuli may increase the 
NUP secretion in diseases involving the right and left ventricles 
in pathological processes [2]. The hemodynamic effects of 
NUP include unloading the heart in response to the increased 
intravascular volume. Increase in their concentration levels in 
the blood indicates the breakdown of the cardiovascular system 
functioning. There is undoubted evidence of the natriuretic peptide 
system involvement in the pathophysiological mechanisms of 
hypertension (AH), myocardial infarction and atherosclerosis [3, 
6]. Of scientific and clinical interest is the open-ended question of 
changing the NUP levels in the blood in patients with MS, which 
combines the pathology of the cardiovascular system with lipid 
and carbohydrate metabolism disturbances. It should be noted, 
however, that the data of the NUP levels and insulin resistance 
correlation are controversial [2, 4, 5]. 
The purpose of this study was to determine atrial and brain 
NUP levels in the blood plasma of MS patients and to establish 
their correlation with abdominal obesity, the parameters of 
carbohydrate and lipid metabolism. 
Material and Methods
The study involved 52 people (38 women and 14 men, 
mean age 46.6 ±1.62 years). 
A survey of patients was conducted in accordance with the 
Helsinki Declaration of the World Association “Recommendations 
for physicians involved in biomedical research involving human 
subjects” (2001), and after getting signed informed consent from 
the patients. 
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For the diagnosis of MS, criteria relevant for the national 
guidelines RSSC (Russian Scientific Society of Cardiology) for 
diagnosis and treatment of MS (2009) were applied [6]. Exclusion 
criteria were chronic heart failure and coronary heart disease. In 
accordance with the criteria selected, the patients were divided 
into two groups: the control group (1st) included 12 apparently 
healthy persons; the observation group (2nd) which included 40 
patients with MS. 
A general clinical examination was performed, including 
anthropometry to identify abdominal obesity. The total 
cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), 
and triglyceride (TG) levels were determined in the venous blood 
using the A-25 Biosystems Autoanalyzer (Germany) and the 
“Olveks” sets (Ukraine). Low-density lipoprotein cholesterol 
(LDL-C) was calculated according to Fridvald’s formula. Fasting 
glucose and insulin were also determined, and the Homa index 
was calculated. The pro-ANP and N-terminal fraction of BNP 
(NT-proBNP) levels in plasma were determined by enzyme 
immunoassay (AxSYM, Norway) using the commercial kits 
(pro-ANP (1-98) and proBNP (1-108)  of  the “Bimedica GmbH” 
(Austria). 
Statistical data processing was performed using the 
software package Statistica 6.0 for Windows. Pearson’s 
Correlation Coefficient (r) was used to determine the strength of 
the relationship between the two continuous variables. P value 
less than 0.05 was considered significant.
Results and Discussion
In all patients in the observation group, abdominal obesity 
was diagnosed.  The Quetelet index in the examined persons was 
equal to 30.10 ± 0.87, a waist size for women – 93.66 ± 3.04, for 
men – 99.37 ± 4.41 (Table 1). Hypertension stage 1 was defined in 
39.13% of persons; 56.52% of patients had stage 2 hypertension. 
On laboratory examination the cholesterol level in 56.5% of MS 
patients was increased by 27.6%, while the concentration of 
triglycerides in the blood serum - twice (p<0.001)  in 34.78% of 
the persons, the values   of atherogenic LDL-C were higher than 
the standard in 69.56% of cases, hypoalfacholesterolemia was 
detected in 63.5% of the patients. 
Insulin resistance (IR) was set at 86.5% of the patients by 
the Homa index, which was increased by 1.9 times (p<0.05), but 
it was not accompanied by hyperinsulinemia, and only 11.5% of 
patients with severe hyperinsulinemia showed IR (p<0.001). The 
level of NT-proBNP in MS patients showed that the concentration 
of the NUP studied exceeded that in the control group by 20% 
(p<0.05). The most pronounced changes were found in MS 
patients at the level of pro-ANP. 
To determine the relationships between plasma 
concentrations of the atrial and brain NUP and the clinical 
and biochemical markers of MS, a correlation analysis was 
performed, where r <0.4 - are the weak links, r = 0.4-0.6 is the 
average connection and r >0. 6 - are the strong bonds (Table 2).  
In the control group, strong and significant relationships 
between clinical and laboratory parameters and the peptides 
studied were not established. However, in the group of patients 
with MS, medium and strong significant associations were formed 
between the NUP and laboratory parameters of carbohydrate 
metabolism: NT-proBNP correlated with the insulin levels (r = 
0.55; p > 0.05) and IRI (r = 0.57; p> 0.05), pro-ANP correlated 
with the insulin levels (r = - 0.73; p > 0.05) and IRI (r = - 0.78; p > 
0.05). The correlation between the Quetelet index and the amount 
of plasma NT-proBNP changes was identified in MS patients, 
which was proved by the formation of the links of medium 
strength (r = 0.66; p > 0.05). 
Results  of  the  clinical  studies,  significant  correlations 
between the NUP and insulin levels, and IRI enable us to 
ascertain the relationship between the atrial and brain NUP levels 
in the blood plasma with changes in the metabolic processes in 
MS patients.  
Table 1.
Clinical and laboratory characteristics of healthy persons 
and patients with MS
Parameters
Groups
control
n=12
MS patients
n=40
SBP, mmHg. 117.44±2.71 165.00±3.03**
DBP, mmHg. 72.44±2.78 103.91±2.10**
Quetelet index, U 28.25±0.81 30.10±0.87
Waist size 
Male/Female, sm 
81.33±3.33
73.25±2.38
99.37±4.41**
93.66±3.04**
Fasting glucosa, mmol/L  5.81±0.14 6.12±0.17
Insulin, mcU/ml 9.43±1.44 16.42±1.70**
Homa index, U 2.40±0.80 4.70±0.65*
TC, mmol/L 4.95±0.18 6.32±0.24
TG, mmol/L 1.08±0.19 2.45±0.35**
HDL-C, mmol/L 1.35±0.14 1.05±0.05
LDL-C, mmol/L 3.11±0.12 4.42±0.45*
pro-ANP, nmol/mL 1.46±0.24 2.45±0.80*
NT-proBNP, fmol/mL 7.5±0.21 9.12±0.18*
Note: * - p <0.05 and **- P <0.001 - between control group and MS 
patients. 
Table 2.
Correlations between laboratory parameters and natriuretic peptide in 
patients with MS
Parameters
Natriuretic peptide
control MS patients
NT-
proBNP
pro-
ANP
NT-
proBNP
pro-ANP
r r r r
Insulin -0.23 -0.33 -0.73 0.55
Homa index -0.21 -0.34 -0.78 0.57
TC 0.42 -0.13 0.01 -0.05
ТG 0.08 -0.38 -0.29 0.01
LDL-C 0.49 -0.12 -0.08 0.34
HDL-C 0.03 0.25 0.27 -0.20
SBP 0.20 -0.32 -0.31 0.34
DBP 0.23 -0.08 -0.34 0.24
Weight 0.23 -0.45 -0.42 0.27
Quetelet index -0.02 -0.45 -0.66 -0.21
Note: Bold and italics type marked a strong connection, only bold type 
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The main criterion of the metabolic syndrome - abdominal 
obesity- leads to insulin resistance, and further development of 
the metabolic changes plays a significant role. It is known that 
visceral fat synthesizes a number of hormones and bioactive 
substances (leptin, free fatty acids, angiotensin, etc.) [1, 5, 8]. It 
is important to note that in abdominal obesity, adipocytes are a 
source of proinflammatory cytokines. The literature highlights the 
effect of the cytokines on the myocardium, mainly tumor necrosis 
factor-alpha (TNF-α), which has directly damaging effects on the 
cardiomyocites, due to the presence of the expressed so-called 
«death receptors» on the surfaces of adult cardiomyocytes. 
TNF-α binds to the aforementioned receptors and initiates the 
process of apoptosis [9]. 
Today, we know that the reasons for the exchange 
and functional impairment in MS are insulin resistance 
and compensatory hyperinsulinemia. Insulin resistance 
leads to endothelial dysfunction and an imbalance in the 
vasoactive mediators leading to the enhanced secretion by the 
vasoconstrictors. Hyperinsulinemia acting on the kidneys and 
the hypothalamic-pituitary system increases the activity of the 
sympathetic nervous system, which in turn triggers the cascade 
of reactions leading to the heart and vascular remodeling. In MS 
the renin-angiotensin-aldosterone system (RAAS) is activated, 
increasing the total peripheral vascular resistance leading to the 
development of hypertension [5, 7, 8]. Thus, in MS the NUP level 
in the blood plasma increases. This process is due to the activation 
of the RAAS and sympathetic nervous system, a violation of the 
endothelial function of the blood vessels, an imbalance in the 
vasoactive mediators [5, 8] and increased cytokine secretion 
[9]. In this case, the remodeling of the heart occurs not only 
by hemodynamic overload, but also due to the influence of the 
humoral factors. Myocardial injury occurs during the active 
release of NUP. The natriuretic hormone counteracting the 
effect of the prior mentioned factors enables the neurohormonal 
protection of the heart. 
Thus, the connection between the plasma levels of the 
atrial and brain NUP and the components of MS allows us to 
consider NUP levels as markers for the early diagnosis of MS.
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